Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. has announced amendments to its debt facility with Avenue Capital Group, extending the interest-only period to support ongoing clinical trials. The baseline interest-only period has been extended by three months, with options for further extensions contingent on achieving specific milestones. Additionally, the draw period for a tranche of the facility has also been extended, providing the company with enhanced financial flexibility. In exchange for these amendments, Recce will issue additional warrants to Avenue Capital Group.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement Recce Pharmaceuticals Secures Extended Interest-Only Period Under Avenue Capital Debt Facility Highlights: • Interest-only extension: Extended to 31 December 2026, with scope for further extension to 30 September 2027 conditional on equity funding and clinical milestones •...
Recce Pharmaceuticals Ltd. on 6ix
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals